Skip to content

In vitro COagulation Dynamics of conformational changes in ADAMTS13

In vitro COagulation Dynamics of conformational changes in ADAMTS13

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON25418
Enrollment
12
Registered
2021-01-09
Start date
2021-01-19
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Male - Age 18-35

Exclusion criteria

Exclusion criteria: - Participation in a scientific intervention study in the last 3 months - No informed consent - History of coagulation disorders - Active use of prescription medication - Use of anticoagulant medication, including aspirin - History of liver disease - History of chronic transmittable disease - History of alcohol, smoking or drug abuse

Design outcomes

Primary

MeasureTime frame
ROTEM lysis, EXTEM/FIBTEM/ABTEM (i.e. LT, LOT, Li (t), ML, CLR), measured on the day of the blood draw

Secondary

MeasureTime frame
ADAMTS13 plasma determinations (antigen, activity, conformation, degradation) Plasma turbidity (time to onset, slope, degree) Whole blood clot lysis, using HALO assay (time to onset, slope, degree), Platelet activation (CD62P, PAC1), using flow cytometry Platelet adhesion and aggregation, using flow model (Time to platelet adhesion, aggregation and breakdown of clots, measured using fluorescent live-cell imaging). *There will be only one blood draw (and thus one timepoint) for the volunteer. All outcomes except the ADAMTS plasma determinations. will be measured on the day of thid blood draw. The ADAMTS13 plasma determinations will be performed on a later moment on frozen plasma obtained from the inital blood draw.

Contacts

Public ContactPieter Sloos

Amsterdam UMC, location AMC

p.h.sloos@amsterdamumc.nl+3125668222

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)